Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cell.2016.01.049 http://scihub22266oqcxt.onion/10.1016/j.cell.2016.01.049 C4788788!4788788!26967289     free     free     free       Cell 2016 ; 164 (6): 1233-47 Nephropedia Template TP {{tp|p=26967289|t=2016. The Basis of OncoImmunology |pdf=|usr=}}{{26967289}} gab.com Text The Basis of OncoImmunology JO: Cell http://www.kidney.de/pget.php?&tw=1&pmid=26967289 #FOAvip Cancer heterogeneity, which enables clonal survival and treatment resistance, is shaped by active immune responses. Antigen-specific T cells can control cancer, as revealed clinically by immunotherapeutics such as adoptive T?cell transfer and checkpoint blockade. The host immune system is thus a powerful tool that if better harnessed could significantly enhance the efficacy of chemotherapeutics and improve outcomes for cancer sufferers. To realize this vision, however, a number of research frontiers must be tackled. These include developing strategies for neutralizing tumor-promoting inflammation, broadening T cell repertoires (via vaccination), and elucidating the mechanisms by which immune cells organize tumor microenvironments to regulate T cell activity. Such efforts will pave the way for identifying new targets for combination therapies that overcome resistance to current treatments and promote long-term cancer control. Twit Text FOAVip The Basis of OncoImmunology ????Cell http://www.kidney.de/pget.php?&tw=1&pmid=26967289 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26967289 #FOAvip English Wikipedia <ref>{{Cite pmid|26967289}}</ref> The Basis of OncoImmunology #MMPMID26967289 Palucka AK; Coussens LM Cell 2016[Mar]; 164 (6): 1233-47 PMID26967289show ga Cancer heterogeneity, which enables clonal survival and treatment resistance, is shaped by active immune responses. Antigen-specific T cells can control cancer, as revealed clinically by immunotherapeutics such as adoptive T?cell transfer and checkpoint blockade. The host immune system is thus a powerful tool that if better harnessed could significantly enhance the efficacy of chemotherapeutics and improve outcomes for cancer sufferers. To realize this vision, however, a number of research frontiers must be tackled. These include developing strategies for neutralizing tumor-promoting inflammation, broadening T cell repertoires (via vaccination), and elucidating the mechanisms by which immune cells organize tumor microenvironments to regulate T cell activity. Such efforts will pave the way for identifying new targets for combination therapies that overcome resistance to current treatments and promote long-term cancer control. äThe Basis of OncoImmunology (epmc).pdf DeepDyve Pubget Overpricing